Human H-ferritin presenting RBM of spike glycoprotein as potential vaccine of SARS-CoV-2

The outbreak of COVID-19 has so far inflicted millions of people all around the world and will have a long lasting effect on every aspect of everyone's life. Yet there is no effective approved treatment for the disease. In an effort of utilizing human ferritin as nanoplatform for drug delivery,...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv 2020-06
Main Authors: Yao, Dehui, Lao, Fang, Zhang, Zeyi, Liu, Yan, Cheng, Jianwei, Ding, Fengjiao, Wang, Xiaofei, Lun Xi, Wang, Chuang, Xichong Yan, Zhang, Rongkun, Ouyang, Fangxing, Ding, Hui, Ke, Tianyi
Format: Article
Language:English
Subjects:
ACE2
Angiotensin-converting enzyme 2
Biological activity
Coronaviruses
COVID-19
Drug delivery
Ferritin
Fusion protein
Glycoproteins
N-Terminus
Protein structure
Proteins
Severe acute respiratory syndrome coronavirus 2
Spike glycoprotein
Vaccines
Citations: Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The outbreak of COVID-19 has so far inflicted millions of people all around the world and will have a long lasting effect on every aspect of everyone's life. Yet there is no effective approved treatment for the disease. In an effort of utilizing human ferritin as nanoplatform for drug delivery, we engineered a fusion protein by presenting receptor-binding motif (RBM) of SARS-CoV-2 virus spike glycoprotein on the N-terminus of ferritin subunits. The designed fusion protein with a cage-like structure, similar to that of corona virus, is a potential anti-SARS-CoV-2 vaccine. We hereby show the construction, preparation, and characterization of the fusion protein RBM-HFtn. Our initial affinity study confirmed its biological activity towards ACE2 receptor which suggests its mode of action against SARS-CoV-2 could be either through vaccine therapy or blocking the cellular entry of virus as antagonist of ACE2 receptor. Competing Interest Statement T. Ke holds ownership interest (including patents) in Kunshan Xinyunda Biotech Co., Ltd. No potential conflicts of interests were disclosed by the other authors. Footnotes * More authors were added to reflect their contribution to this work.
DOI:10.1101/2020.05.25.115618